A Single Centre, Two-period, Open Label, Randomised, Cross-over Study to Assess Plasma Levodopa, Carbidopa and Entacapone Concentrations After Continuous Infusion of TRIGEL or Duodopa in Patients With Advanced Parkinson´s Disease

Trial Profile

A Single Centre, Two-period, Open Label, Randomised, Cross-over Study to Assess Plasma Levodopa, Carbidopa and Entacapone Concentrations After Continuous Infusion of TRIGEL or Duodopa in Patients With Advanced Parkinson´s Disease

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Dec 2016

At a glance

  • Drugs Levodopa/carbidopa/entacapone (Primary)
  • Indications Parkinson's disease
  • Focus Pharmacokinetics
  • Sponsors LobSor Pharmaceuticals
  • Most Recent Events

    • 17 Dec 2016 Results assessing safety and efficacy published in the Movement Disorders.
    • 19 Apr 2016 Treatment arm changed from 1 to 2, with 2 interventions TRIGEL first, then Duodopa and Duodopa first, then TRIGEL.
    • 02 Nov 2015 Results were published in a LobSor Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top